Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Aug 20, 2026 8:10 am EDT

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

Aug 13, 2026 9:10 am EDT

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

Aug 12, 2026 8:30 am EDT

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

Aug 06, 2026 8:05 am EDT

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

Aug 05, 2026 8:30 am EDT

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

Jul 29, 2026 8:25 am EDT

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Jul 27, 2026 8:32 am EDT

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Jul 14, 2026 8:32 am EDT

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Jul 06, 2026 8:11 am EDT

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

Jun 25, 2026 8:12 am EDT

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2026 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023